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ABSTRACT  
Objective: In the present work attempt has been made to stabilize optimized nanosuspensions of glimepiride by solidification using a novel Oral 
Thin Film (OTF) formulation. 
Methods: Nanosuspensions were characterized for particle size, zeta potential as well as in vitro dissolution profile. As nanosuspensions are prone 
to destabilization by Ostwald’s ripening or agglomeration/aggregation, OTF formulation as a novel approach for stabilization through solidification 
of optimized nanosuspension was attempted. OTF formulation method is a simple, easy and scalable method for the preparation of solid oral dosage 
form. Prepared formulations were evaluated for physicochemical parameters like folding endurance, disintegration time, tensile strength, in vitro 
drug release, in vivo bioavailability and stability. 
Results: The mean particle size of the nanoparticles in OTF was found to be 57.2 nm. It was observed from the results of in vivo bioavailability stud-
ies that high plasma drug concentrations(Cmax) were achieved for nanosuspension loaded OTF (NSOTF) i.e. 4900 ng/ml as compared to marketed 
oral formulation (Cmax-2900 ng/ml). Results of the stability studies indicated that nanosize of the particles was retained even after 3 mo of the 
study.  
Conclusion: Therefore it can be concluded that OTF formulation has a potential for stabilization of nanosuspensions.  
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Nanotechnology-based techniques have been valuable in improving 
the solubility of poorly water soluble drugs [1]. Nanosuspensions in 
many cases have given good results in improving saturation solubili-
ty by increasing the surface area available for dissolution [2]. Vari-
ous researchers have reported the development of nanosuspensions 
with high drug loading, increased dissolution and better bioavaila-
bility [3, 4]. Studies have also been done to report non-toxic nature 
of these nanosuspensions [5]. Stability of nanosuspension is the 
major challenge associated with it. These are thermodynamically 
unstable and tend to show particle growth during storage. The 
change in particle size reverses all the advantages of solubility, dis-
solution and bioavailability. Various stabilizers like hydrophilic 
polymers [6-8] non-ionic or ionic surfactants and food proteins [9] 
have been used for stabilizing particle size of nanosuspensions, but 
the efficacy of these stabilizers is questionable upon dissolution, 
high temperature and pH changes. Further, as solidified form of 
nanosuspension is preferred over liquid form, significant work is 
reported on solidification techniques of nanosuspensions. These are 
solidified either using spray dryer [10, 11] or freeze dryer [12]. But 
it was observed that both of these techniques involve the control of 
multiple process parameters and still have problems of agglomera-
tion during storage. Nanosuspensions have also been converted to 
hydrogels for the purpose of drug delivery and stability [13], but 
these hydrogels contain a large amount of water so may not be a 
system of choice for moisture sensitive drug. 
Recently attempts have also been made to convert nanosuspensions 
into thin film formulation that offer both stability and ease of admin-
istration [14, 15]. Thin films can further improve the solubility of 
drugs. Improved stability and bioavailability have been demonstrat-
ed [16, 17] for poorly water soluble drugs. 
Glimepiride is one of the third generation sulfonyl urea used for the 
treatment of type 2 diabetes. It belongs to class II of Biopharmaceu-
tical classification system showing poor aqueous solubility (0.0082 
mmol) and high permeability [18]. Several attempts have been made 
to improve solubility of Glimepiride using approaches like solid 
dispersion [19] inclusion complexation [20] co-solvency [18] etc. 
But no systematic studies have been reported for enhancement of 
solubility using nanosuspension technique. 
In the present work, an attempt has been made to prepare nanosus-
pension by using high shear homogenization to improve solubility of 
glimepiride and to improve the stability of glimepiride loaded nano-
suspension by formulating into OTF. 
MATERIALS AND METHODS 
Materials 
Glimepiride and Hydroxypropyl methylcellulose (HPMC) E 15 were 
obtained as gift samples from Zim Laboratories ltd., Nagpur, India. 
Sodium Dodecyl Sulfate (SDS) (Merck, Mumbai, India), PEG 400 
(Loba Chemie Ltd. Mumbai, india) were procured commercially. All 
other chemicals and reagents were of analytical grade and were 
used without further purification.  
Preparation of glimepiride nanosuspension by high shear ho-
mogenization 
Glimepiride loaded nanosuspensions were prepared using high shear 
homogenization method. Stabilizer solution was prepared using 1% 
HPMC and 12% SDS. The concentration of both of these stabilizers was 
selected during preliminary trials. The solution was stirred using high 
shear homogenizer (Remi-RQT-127 A/D, Mumbai, India) at 4000 rpm 
for 15 min. Glimepiride (0.4 g) was then added to this solution while 
stirring and homogenization was continued at 8000 rpm for 150 min 
at ambient conditions. To study the effect of stirring time on nanosus-
pension properties, above procedure was repeated by increasing ho-
mogenization time to 180 min. Clear nanosuspensions so obtained 
were labeled as GNS1 and GNS2 and were stored in capped glass vials 
till further evaluation at room temperature. 
Evaluation of glimepiride nanosuspensions 
Particle size distribution and polydispersity index 
Particle size was determined using Photon correlation spectroscopy 
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(PCS) using Horiba Nanoparticle Analyser (Nanopartica SZ-100). 
This analysis yields the mean particle diameter (z-average), Polydis-
persity index and zeta potential at 25 °C.  
Percent drug content 
An aliquot (0.1 ml) of nanosuspension was diluted to 10 ml with 
methanol and filtered through 0.45 µm filter paper. The sample was 
analyzed using UV Spectrophotometer (Shimadzu-1700, Japan) at 
λmax of 233 nm using methanol as blank. Each sample was prepared 
and analyzed in triplicate. 
Saturation solubility studies 
Saturation solubility measurements were carried out for both pure 
drug and GNS1 and GNS2 using UV spectroscopy. Pure glimepiride 
(10 mg) and nanosuspensions (GNS1 and GNS2) (equivalent to 10 
mg Glimepiride), were weighed and separately introduced into 250 
ml Stoppard conical flask containing 10 ml of distilled water. The 
flask was sealed and placed in a rotary shaker at 37 °C and equili-
brated for 2 d. The contents were then filtered, and the suitably 
diluted samples were analyzed using UV-Visible spectrophotometer 
(Shimadzu-1700, Japan) at 233 nm, against distilled water as a 
blank. Each sample was prepared and analyzed in triplicate.  
In Vitro dissolution studies  
In vitro drug release studies were performed on USP-Type II Basket 
apparatus at 75 rpm in two dissolution media separately, 900 ml of 
pH 1.2 buffer and 900 ml of pH 6.8 phosphate buffer at 37.0±0.5 °C. 
TheHard gelatin capsules were filled with an accurately weighed 
quantity of pure glimepiride powder (2 mg) and GNS1 and GNS2 
(equivalent to 2 mg of glimepiride) were used for dissolution. About 
5 ml of sample was withdrawn at predetermined time intervals and 
replaced with an equal quantity of fresh dissolution medium. These 
samples were filtered through 0.45-μm Whatman filter paper and 
analyzed spectrophotometrically at λmax 227 nm. The in vitro dissolu-
tion testing studies were performed in triplicate. 
Preparation of glimepiride OTFs 
OTFs of optimized glimepiride nanosuspension were prepared by 
solvent casting method [16]. Accurately weighed quantities of HPMC 
E-15 (1 g) and PEG 400 (0.15 g) were added to glimepiride nanosus-
pension formulation GNS2 (equivalent to 40 mg of glimepiride) and 
stirred using magnetic stirrer for 30 min. The final mixture was then 
casted on a glass plate with the help of doctor’s blade. It was dried in 
hot air oven for 2 h at 50 °C. After drying, films were removed with 
the help of the sharp blade, cut in the suitable sizes containing 
glimepiride equivalent to 2 mg, packed in aluminum foil and kept in 
a desiccator till further evaluation. The films were labeled as NSOTF. 
The procedure was repeated for the formulation of OTFs of pure 
glimepiride powder and films so obtained were labeled as GOTF. 
Evaluation of OTFs 
Thickness 
The thickness of the films was measured using the digital 
micrometre with an accuracy of 0.001 mm. Thickness was measured 
for 10 different films and average thickness was determined. 
Tensile strength and percent elongation 
Tensile strength was determined using lab scale tensile strength to 
measure instrument. Films of dimension 3×2 cm2and free from 
physical imperfections were used for the study. The films were held 
between two clamps at a distance of 3 cm. Films were pulled by the 
upper clamp at the rate of 5 mm per minute until it tears with the 
addition of weight at regular intervals. Measurements were done in 
triplicate for each batch. Tensile strength is the ratio of maximum 
stress applied to a point at which the film specimen breaks and can 
be computed from the applied force at rupture to the cross-sectional 
area of the fractured film as a mean of three measurements and 
described in the equation:  
 
Percent elongation was calculated using the following formula:  
 X 100 
Folding endurance 
Folding endurance is determined by repeated folding of the strip at 
the same place till the strip breaks. The number of times the film is 
folded without breaking is computed as the folding endurance value. 
The folding endurance studies were performed for six strips for each 
batch i.e. NSOTF and GOTF. 
Percent moisture absorption 
The moisture absorption capacity of the films was determined by 
exposing the pre-weighed films to 75±2% relative humidity (created 
by using a saturated solution of NaCl) in a desiccator at room tempera-
ture. Film samples were weighed at predetermined intervals until 
constant weight was achieved. Percentage moisture uptake was calcu-
lated as the percentage of the difference between the final and initial 
weight with respect to the final weight as per the following formula:  
 
Disintegration test 
Disintegration test was performed in the USP Disintegration appa-
ratus. Simulated salivary fluid (pH 6.8) was used as the medium. The 
films were placed in the tubes of the container, and the disks were 
placed over it. The average disintegration time of six films was noted 
for both the batches.  
Percent drug content 
Six strips from each batch were picked randomly and were weighed 
individually. Each film was sonicated with methanol (10 ml) for 2 h. 
The final mixture (1 ml) was filtered through 0.45 filter and suitably 
diluted with methanol. The UV absorbance of the solution was 
measured at 227 nm, using methanol as blank. An average of six 
films was reported as average drug content. 
In vitro dissolution studies 
In vitro dissolution studies of NSOTF (containing nanoparticles) and 
GOTF (containing pure Glimepiride) were performed in 900 ml of 
pH 1.2 HCl buffer at 37±0.5 °C using USP Type II (Paddle) Dissolu-
tion apparatus at 75 rpm. Aliquots (5 ml) were collected at specific 
time intervals and the volume was made up by adding fresh dissolu-
tion medium. Glimepiride was determined spectrophotometrically 
(UV 1800, Shimadzu, Japan) at λmax 227 nm. Studies were repeated 
using 900 ml of pH 6.8 phosphate buffer as a dissolution medium 
also. Results are expressed as the mean of three determinations. 
Dissolution studies of glimepiride marketed tablets were also car-
ried out using both the dissolution media for comparison purpose.  
In vivo studies of glimepiride OTF 
The protocol of animal study was approved by the institutional ani-
mal ethics committee. Rabbits of either sex (Weight, 2-3 kg) were 
fasted overnight before the studies. The rabbits were randomly 
divided into three groups of six animals each. The Group I was given 
GOTF, Group II, NSOTF and Group III were given marketed tablet. 
Both the films and a tablet containing 2 mg of glimepiride were dis-
persed separately in 5 ml of water, and the dispersion was carefully 
fed to animals using glass syringe without needle ensuring the com-
plete administration. Blood samples for pharmacokinetic analysis 
were withdrawn at intervals of 0, 1h, 2h, 4h, 6h, 8h and 12 h from the 
marginal ear vein. Blood samples were collected in heparinized tubes 
and centrifuged for 10 min at 5,000 rpm in a refrigerated centrifuge. 
The plasma samples were then stored at-4 °C till further analysis. 
Plasma analysis 
About 2 ml of chloroform was added to plasma (0.5 ml) and vor-
texed for 5 min. The mixture was centrifuged at 5000 rpm for 10 
min; the chloroform layer was then evaporated to dryness. The 
residue so obtained was reconstituted in 2 m1 of the mobile phase, 
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filtered and was analysed for glimepiride content using HPLC (Ag-
ilent Technologies) using following conditions:  
Column: Eclipse XDB, C18 
Mobile Phase: Acetonitrile: Water: : 90:10 
Flow Rate: 1 ml/min 
Sample Size: 20 μl 
UV Detection wavelength: 228 nm 
Stability studies 
Both NSOTF and GOTF formulations were subjected to accelerated 
stability studies as per ICH guidelines at 45 °C, 75% RH. Film sam-
ples were evaluated after 1, 2 and 3 mo for disintegration time, 
mean particle size and dissolution profile to study the stability of 
nanosuspension loaded OTFs. 
RESULTS AND DISCUSSION 
Evaluation of glimepiride nanosuspension 
Attempts to improve solubility of poorly soluble glimepiride has 
been made several times, but no report in literature is available for 
the nanosuspension formulation of glimepiride for improving its 
solubility. Nanosuspensions of glimepiride were prepared using high 
shear homogenizer at a constant speed for 150 to 180 min. The aim 
was to study the effect of homogenization time on the characteristics 
of nanosuspensions. The particle size, polydispersity index and zeta 
potential are given in table 1. The table shows that homogenization 
time has the profound impact on the particle size and polydispersity 
index. Increasing the homoginization time reduces the mean particle 
size from 160.6 nm to 98.1 nm. Polydispersity Index was found to be 
0.042 for GNS1 and 0.562 for GNS2. Polydispersity index is the indi-
cator of uniformity in particle size distribution. The obtained value 
indicated the uniformity in particle size distribution in both the formu-
lations. Fig. 1 depicts the particle size distribution of GNS2. From table 
2 it was seen that percent drug content of GNS1 and GNS2 was 92.95% 
and 95.42% respectively indicating that increasing homogenization 
time reduces the particle size and hence increases the drug content in 
the clear fraction of nanosuspension. Because of higher drug content, 
saturation solubility of GNS2 is more than GNS1. 
 
 
Fig. 1: Particle size distribution of GNS2 
 
Table 1: Particle size, polydispersity index and zeta potential of glimepiride loaded nanosuspensions 
Formulation code Mean particle size (nm) Polydispersity index Zeta potential (mV) 
GNS1 160.6±84.2 0.042 -99.6 
GNS2 98.1±2.2 0.562 -18.2 
GNS-glimepiride nanosuspension, mean±SD (n=3) 
 
Table 2: Percent drug content and saturation solubility of glimepiride loaded nanosuspensions 
Formulation code *Percent drug content *Saturation solubility (mcg/ml) 
Glimepiride --  
GNS1 92.95±0.25 669.57±1.47 
GNS2 95.428±1.09 814.17±0.15 
*mean±SD (n=3) 
 
In vitro dissolution studies of glimepiride nanosuspensions 
In vitro dissolution studies revealed that nanosuspension formula-
tions resulted in a dramatic increment in the glimepiride solubility. 
Both GNS1 and GNS2 showed almost complete drug release within 
10 min whereas pure glimepiride dissolved only up to 25% in first 
10 min. GNS1 and GNS2 showed a similar release profile in pH 1.2 
and pH 6.8 phosphate buffer. This shows that solubility of 
glimepiride loaded nanosuspension is independent of the pH of the 
surrounding medium. In the earlier studies conducted on 
glimepiride 40 to 75% improvement in dissolution rate was ob-
served in case of solid dispersions prepared using PVP k-30 as com-
pared to pure drug whereas solid dispersions prepared using guar 
gum could release only 30% drug within 10 min. [21,22]. Therefore 
it can be said that formulating nanosuspensions of glimepiride by 
simple high shear homogenization method using hydrophilic poly-
mer HPMC E-15 which acts as a steric stabilizer could enhance dis-
solution rate significantly [23]  
The increase in dissolution profile of GNS2 may be due to an in-
crease in the stirring times during preparation as compared to their 
respective nanosuspension formulations, which resulted in smaller 
particle sizes. As the size decreases, the effective increase in particle 
surface area results in an increase in dissolution velocity according 
to the Nernst Brunner-Noyes Whitney equation [24]. 
A large surface area-to-volume and higher apparent saturation solu-
bility of nanoparticles pronouncedly enhanced the dissolution rate. 
Finally, the increase in surface wetting by the surfactants in the 
nanosuspension formulations most likely results in further en-




Fig. 3: In vitro dissolution profiles of GNS 1, GNS 2 and pure 
glimepiride inpH 1.2 HCl buffer 
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Fig. 4: In vitro dissolution profiles of GNS 1, GNS 2 and pure 
glimepiride in pH 6.8 phosphate buffer 
 
Solidification of nanosuspensions in various ways like spray drying, 
freeze drying has been explored by many researchers for two rea-
sons, one is to formulate the nanosuspension in a suitable unit dos-
age form and second is to improve their stability. The biggest draw-
back of nanoparticles is they tend to form aggregates upon standing. 
Many researchers have used various types of stabilisers in optimized 
concentrations to improve the stability of nanosuspensions [25]. In 
the present work, an attempt was made by converting nanosuspen-
sions into thin flat films. The film forming polymer and plasticizers 
were added to the dispersion containing nanosuspension. The high 
viscosity of the final dispersion prevents the nano suspended parti-
cles from forming aggregates. After casting and drying the stability 
of the particles is ensured better [26]. 
Table 3 shows the comparison of physicochemical characterization 
of pure glimepiride films (GOTF) and nanosuspension loaded 
glimepiride films (NSOTF). Both the films were found to be non-
sticky, translucent with a smooth surface. NSOTF showed good me-
chanical properties. All the physicochemical properties were found 
to be comparable in both the films. This may be because there are 
minor differences in the composition of both the films. The assay (% 
drug content) of nanosuspension loaded films was within the IP 
limits because of better mixing efficiencies are achieved in smaller 
and uniformly suspended particles. 
 
Table 3: Physicomechanical characterization of NSOTF 
S. No. Parameters Formulation code 
GOTF NSOTF 
1 Appearance *Translucent film with smooth surface *Translucent film with smooth surface 
2 Average weight 45.66±0.32 47.08±1.10 
3 Thickness (mm) 0.136±0.5 0.141±0.032 
4 Tensile strength (N/mm2) 7.83±0.17 7.95±0.12 
5 Percent Elongation 16.98±0.58 18.25±1.68 
6 Folding endurance  15±3 20±2 
7 (%) Moisture Absorption  8.85±0.23 9.35±0.14 
8 Disintegration Time (sec) 29.15±1.12 27.84±0.95 
9 Drug content (%) 95.480 98.030 
* mean±SD (n=3) 
 
Fig. 5 and 6 gives comparative in vitro dissolution profile of GOTF, 
NSOTF and marketed tablets in pH 1.2 and 6.8. Fig. reveals that mar-
keted tablets showed less than 30% dissolution in both the media. 
An important finding of this work as that OTFs improve dissolution 
of the poorly soluble drugs. NSOTF showed more than 95% dissolu-
tion in both the dissolution media. 
 
 




Fig. 6: Comparative in vitro dissolution profile of GOTF and 
NSOTF in pH 6.8 phosphate buffer 
In vivo pharmacokinetic studies of glimepiride nanosuspen-
sions 
The differences in between the formulations were more evident 
during in vivo studies (table 4). Plasma concentration of 
glimepiride increased more rapidly in case of NSOTF than in 
GOTF and marketed tablets. The t-max was 2 h and Cmax was 
4900ng/ml for NSOTF which was highest among all the three 
formulations, whereas marketed tablet showed lowest Cmax 
(2900ng/ml). Area under the curve (AUC) values calculated for 
12 h from the plasma concentration of glimepiride by Trapezoi-
dal rule. The values have significantly increased from 22650ng. 
h/ml to 27800 ng. h/ml by converting glimepiride into OTFs. 
This effect is due to the complete dissolution of glimepiride in 
the GI tract. Formulation NSOTF showed the highest AUC (37444 
ng. h/ml) i.e. significant enhancement in bioavailability. Thus 
nanosuspension loaded OTFsis a better and novel option for 
improvement of bioavailability with a faster onset of action of 
poorly soluble drugs. 
 
 
Fig. 7: In vivo drug release profiles of GOTF, NSOTF and market-
ed tablet
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Table 4: Pharmacokinetic parameters of GOTF, NSOTF and marketed tablet 
S. No. Parameter NSOTF GOTF marketed tablet 
1 Cmax (ng/ml) 4900  3600 2900 
2 tmax (h) 2h 4h 4h 
3 AUC (ng. h/ml) 37444 27800 22650 
 
Stability studies 
From stability studies of OTFs (table 5) it was observed that the 
physicochemical properties were retained within the specified limits 
i.e. films were transparent visually, and percent moisture absorption 
increased from 9.35 to 10.27 % which did not affect the ease of han-
dling of the film as well as folding endurance was also within limits. 
Film disintegrated within 28 sec and % drug content decreased from 
98.03% to 96.78% within 3 mo at 40 °C/75%RH. There was no sig-
nificant difference in % dissolution of the drug in 1.2 as well as 6.8 
pH (fig. 8 and fig. 9). 
The particle size of the drug dispersed in the OTF was measured 
using Horiba Nanoparticle Analyzer at 25 °C and scattering angle90 
°C. From table 6 it can be seen that particle size of the drug reduced 
from 98.1 nm to 57.2 nm. There was no significant change in the zeta 
potential. This may be because of the presence of HPMC E-15 in the 
film base which helps in preventing crystallisation of drug particles 
as well as causes drug solubilization [27,28] along with other excipi-
ents used as a film base like PEG 400. 
  
Table 5: Physicochemical parameters of NSOTF during stability studies 
S. No. Parameters *Initial (at 0 mo) *after 3 mo 
NSOTF NSOTF 
1 Appearance Transparent Transparent 
2 Weight variation (mg) 45.085±1.10 44.059±1.23 
3 Thickness (mm) 0.131±0.032 0.130±0.25 
4 Tensile strength (N/mm2) 7.85±0.12 8.48±0.22 
5 % Elongation 17.25±1.68 19.18±1.02 
6 Folding endurance 20±2  25±2 
7 (%) moisture absorption 8.35±0.14 10.27±1.47 
8 Disintegration (sec) 27.84±0.95 26.25±0.52 
9 Surface pH 6-7 6-7 
10 Drug content (%) 98.030 96.78 
 *mean±SD (n=3) 
 
 
Fig. 8: In vitro dissolution studies on NSOTF in pH 1.2 buffer 
 
 
Fig. 9: In vitro dissolution studies on NSOTF in pH 6.8 buffer
Table 6: Particle size and zeta potential of NSOTF (Nanosuspension OTF of glimepiride) 
Formulation  Particle size at 0 mo Particle size after 3 mo Zeta potential at 0 mo Zeta potential after 3 mo  




From the above findings, it can be concluded that formulation of 
nanosuspension loaded OTF can be a novel option for stabilisation 
as well as solidification of nanosuspensions. In this work Simple high 
shear homogenization method led to the formation of nanosuspen-
sion with significant improvement in dissolution rate. Transfor-
mation of nanosuspension into OTF stabilized nanoparticles by re-
taining particle size in nano range. Improved bioavailability of the 
drug in OTF formulation was evident from high Cmax and tmax 
values. Thus OTF formulation as a solidification technique can be 
very promising for stabilization of nanosuspensions. 
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